fbpx
Medical Innovation Exchange

Iovance sinks 50% as pivotal cell therapy data disappoint investors, but approval plan pushes ahead anyway

https://www.fiercebiotech.com/biotech/iovance-sinks-50-pivotal-cell-therapy-data-disappoint-investors-pushes-ahead-approval-plan

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.